- Home
- PMI vs PRLD Comparison
PMI vs PRLD Comparison
Compare PMI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMI | PRLD |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 207.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PMI | PRLD |
|---|---|---|
| Price | $0.95 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 159.2K | ★ 195.2K |
| Earning Date | 03-25-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $0.92 | $0.61 |
| 52 Week High | $13.68 | $4.19 |
Technical Indicators
Market Signals| Indicator | PMI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 59.50 |
| Support Level | N/A | $1.02 |
| Resistance Level | $1.37 | $4.10 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 6.89 | 72.41 |
Price Performance
Historical ComparisonAbout PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.